A congenital heart defect is a problem with the structure of the heart. It is present at birth. Congenital heart defects are the most common type of major birth defect.
The Adolescent and Adult Congenital Heart Disease (ACHD) Program at Cincinnati Children's Hospital Medical Center is one of a handful of programs in the nation to be awarded accreditation by the Adult Congenital Heart Association (ACHA).
In a first-in-children randomized clinical study, medical researchers at the University of Maryland School of Medicine and the Interdisciplinary Stem Cell Institute at the University of Miami Miller School of Medicine have begun testing to see whether adult stem cells derived from bone marrow benefit children with the congenital heart defect hypoplastic left heart syndrome (HLHS).
Selexipag is approved for long-term treatment of pulmonary arterial hypertension (PAH) in adults with moderate to severe symptoms.
Caring for an infant begins long before birth. Expectant moms are advised to avoid smoking and drinking, watch what they eat, and follow a host of other recommendations that are in the best interest of themselves and their little one on the way.
Arterial switch to the 12 o'clock position is associated with abnormal coronary perfusion in adolescence, reveals research presented today at EuroCMR 2016.1 Babies born with transposition of the great arteries (TGA) undergo the arterial switch operation in the first days of life.
Surgeons in the Heart Center at Boston Children's Hospital have partnered with Edwards Lifesciences to launch a clinical study of a new prosthetic heart valve for patients born with a congenital heart defect.
What better way to celebrate Valentine's Day than help save a child's heart? That's what Vittoria Flamini, an industry assistant professor in Tandon's Department of Mechanical and Aerospace Engineering, has in mind.
Congenital heart disease is the most common birth defect and the leading cause of all infant deaths in the United States. Mutations in the gene TBX5 have been shown to cause both rare and more prevalent forms of congenital heart disease, yet the underlying mechanisms have remained unclear.
Cornell biomedical engineers have discovered natural triggers that could reduce the chance of life-threatening, congenital heart defects among newborn infants. Those triggers can override developmental, biological miscues, leading to proper embryonic heart and valve formation.
Pregnant women with preeclampsia have a higher risk of delivering an infant with a congenital heart defect. An extensive study of 1.9 million mother and infant pairs by a team at the University of Montreal Hospital Research Centre has shown significant association between these diseases in mothers and newborns from early pregnancy.
Cardiologists from Children's Hospital Los Angeles successfully implanted a Melody Transcatheter Pulmonary Valve in child actor Max Page, the boy who made headlines playing mini Darth Vader in a 2011 Super Bowl ad for Volkswagen.
Children born with the major congenital heart defect hypoplastic left heart syndrome (HLHS) often must undergo a series of corrective surgeries beginning at birth. While most have the standard three-stage Norwood procedure, a hybrid strategy has been introduced to offset some disadvantages associated with the Norwood surgeries. In a report in The Journal of Thoracic and Cardiovascular Surgery, investigators compare whether outcomes can be improved if an arterial shunt is used as a source of pulmonary blood flow rather than the more conventional venous shunt as part of the hybrid strategy of HLHS surgical reconstruction.
The study, published today in the journal Critical Care Medicine and carried out at Royal Brompton Hospital, followed children undergoing surgery for congenital heart disease, and found that by analysing metabolites in the blood -- molecules created as a result of metabolism -- it was possible to predict a child's clinical outcome.
In people, a baby's risk of congenital heart defects is associated with the age of the mother. Risk goes up with increasing age. Newborn mice predisposed to heart defects because of genetic mutations show the same age association.
A team of doctors at Cincinnati Children’s Hospital Medical Center are exploring new avenues to improve surgical preparations and patient care. The hospital recently partnered with the University of Cincinnati’s College of Engineering and Applied Science (CEAS) to produce a 3D printed heart model of a patient with a rare, life-threatening heart condition. 3D printed anatomical models derived from patient scans enable doctors to “practice” surgery in advance and assess possible complications for delicate procedures, improving the outcome of operations.
The Children's Hospital of Philadelphia today launched the Fetal Neuroprotection and Neuroplasticity Program. Building on growing evidence of the interaction of heart disease and brain development in the fetus, this Program will systematically investigate innovative therapies to protect brain development and to prevent brain injury as early as possible before birth.
Loyola University Medical Center has received a three-year accreditation in pediatric transthoracic echocardiography by the Intersocietal Accreditation Commission.
The first post-FDA approval study of a non-surgically implanted replacement pulmonary valve showed strong short- and mid-term results for the device in patients with certain congenital heart defects, according to research presented by a U-M pediatric interventional cardiologist at the American College of Cardiology's 63rd Annual Scientific Session Sunday.
A protein known to promote cancer appears to give the blood vessels strength and shape, researchers report. When yes-associated protein, or YAP, is deleted from vascular smooth muscle cells during development, the protein makes thin-walled blood vessels that over-dilate in response to the usual pressure of blood flow, said Dr. Jiliang Zhou, vascular biologist at the Medical College of Georgia at Georgia Regents University.
Xeltis, a privately held medical device company dedicated to transforming standards of care in heart valve replacement and vascular surgery, has announced that it has finished enrollment in a five-patient feasibility study of implantable products intended to enable for the first time the spontaneous growth of natural, healthy heart valves and vessels. With its proprietary technology, the company has pioneered an entirely new therapeutic category called Endogenous Tissue Growth, or ETG, in which surgeons use unique implants designed to allow the body to repair itself by growing natural, healthy tissue.